HOME
ABOUT
About Hengrui
Meet Our Team
Our Location
R&D
CAREERS
NEWS
CONTACT US
HOME
ABOUT
About Hengrui
Meet Our Team
Our Location
R&D
CAREERS
NEWS
CONTACT US
May 2022
PRESS RELEASE
Jiangsu Hengrui Pharmaceuticals Co., Ltd. launches Luzsana Biotechnology™
Feb 22, 2022
HengRui USA Wins 2022 Top Workplaces Regional Award
April 27, 2021
HengRui USA Announces FDA Grants Orphan Drug Designation of Camrelizumab for "Treatment of Hepatocellular Carcinoma"
Feb 24, 2021
HengRui USA Announces the Launch of In-House Clinical Operations in US with 1st Subject Screened in Study Evaluating SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subject
Feb 05, 2021
HengRui USA Announces First US Patient Screened in Study Evaluating INS068 in Patients with Type 2 Diabetes Mellitus
Nov 28, 2020
HengRui USA Announces Successful Completion of Dosing in Cohort 1 in the Single Ascending Dose Trial with HRS4800